Loading clinical trials...

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) | Clinical Trials | Clareo Health

RECRUITING

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Exploration of A Holistic Management Procedure for Liver Cancer Surveillance in Improving Liver Cancer's Early Diagnosis Efficacy in Chinese Population: Single-Center, Prospective, Observational Real-world Study in EASTERN China

NCT05870969•Ruijin Hospital

View on ClinicalTrials.gov

Summary

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Voluntary participation in the clinical study; fully informed about the study and signed informed consent, willing to follow and capable of completing all trial procedures\[17\]
•2. Age: 18 to 75 years old (including the cut-offs)
•3. Subjects must meet at least one of the following criteria for enrollment.
•1. Patients diagnosed with chronic hepatitis B in hospital or out of hospital: persistent positive hepatitis B surface antigen (HBsAg) for 6 months or more
•2. Patients diagnosed with hepatitis C in hospital or out of hospital
•3. Patients diagnosed with cirrhosis in hospital or out of hospital who meet at least one of the following criteria.
•1. Liver biopsy showing cirrhosis (Ishak score ≥5 or Metavir score = 4);
•2. Liver stiffness measurement (LSM) using FibroScan® (Echosens™, Paris, France) ≥12.0 kPa when TB was normal and ALT ≤ 40 IU/mL, or LSM ≥ 17.0 kPa when TB was normal and ALT \< 200 IU/mL;
•3. Abdominal imaging results showing characteristic of cirrhosis (results showing coarse liver echotexture or nodular, parenchymal, or morphological abnormalities and signs of gastroesophageal varices);
•4. APRI ≥ 2.0;
+6 more criteria

Exclusion Criteria

•Patients meeting any of the following criteria will be excluded from the study:
•1. Age \<18 years or \>75 years
•2. Patients who have been diagnosed with liver cancer before enrollment
•3. Patients with severe mental illness or cognitive impairment
•4. Patients who are pregnant or lactating, or preparing to become pregnant
•5. Patients who have participated in other clinical trials or are participating in other clinical trials within 3 months prior to initiation of study treatment
•6. According to the doctor's judgment, the possibility of the subject being included is low (including inability to understand the project requirements , poor compliance, infirmity, inability to ensure that the protocol can be implemented as required, etc.), or the doctor determines that the subject has any other factors that are not suitable for this study

Locations (1)

Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

March 1, 2023

Primary Completion Date

March 1, 2028

Completion Date

March 1, 2028

Last Updated

May 23, 2023

Enrollment

20,000

ESTIMATED participants

Conditions

Carcinoma, HepatocellularHepatitis C, ChronicHepatitis B, ChronicCirrhosis, LiverNon-Alcoholic Fatty Liver Disease

Interventions

Liver cancer surveillance every 3 months

BEHAVIORAL

Liver cancer surveillance every 6 months

BEHAVIORAL

Liver cancer surveillance annually

BEHAVIORAL

Contacts

Qing Xie, MD

CONTACT

0086-021-64370045 xieqingrjh@163.com

Honglian Gui, MD,PhD

CONTACT

0086-021-64370045 lillian_ghl@163.com

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

NCT04166266

Hepatitis D, ChronicHepatitis B, Chronic

View study

RECRUITING

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

NCT06550622

Hepatitis B, Chronic

View study

RECRUITINGPHASE2

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Inclusion Criteria

Exclusion Criteria

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE